Life
Science

Physics & Engineering

 

Sortieren nach: Datum | Licensing Manager
Home › Technology Offers
Es wurden 2 Technologieangebote gefunden

Immortalized Human Cell Line For HIV Phenotyping


22.10.2009 | Ref.Nr. 07060
Download as PDF PDF Download Share
Life Science › Pharma&Biotech

Globally, the total number of people living with HIV was estimated at 33 million. The clinical development of anti-HIV drugs is currently dominated by the class of entry inhibitors. For infection, the virus uses the coreceptors CCR5 and CXCR4 in addition to CD4 for the entry into target cells. Knowledge of the coreceptor preference is often critical in both the research and clinical settings, especially since coreceptor antagonists entered the market, however current assays are expensive and time consuming.

Here we provide an immortalized human CD4-positive T cell line from a donor homozygous negative for the chemokine receptor CCR5 to determine the coreceptor usage of HIV-1 isolates. The cells are resistant to infection with CCR5-tropic HIV viruses, but are highly susceptible to infection with CXCR4-tropic isolates. This cell line is therefore suitable for a wide range of application: in basic research, e.g. for signal transduction studies, pharmacological studies and clinical application of CCR5 antagonists.

 

IP Rights
A PCT application was filed in November 2008 (priority 2007).

Origin
The technology was developed at the Paul-Ehrlich-Institute, Langen.

Application Area:
Pharma
Development Stage: Prototype
Type of Collaboration: License
Schlagworte: CCR5, CXCR4, HIV, immortalized cell line,
Weitere Kategorien: Diagnostics, Life Science, Immunology & Infection, Immunology & Infection, Pharma & Biotech
Bild des Benutzers Dr. Janin Hofmann
Licensing Manager: Dr. Janin Hofmann
T +49 30 2125 4828
F +49 30 2125 4822
janin.hofmann@ipal.de
Market Potential: Worldwide
Benefits:
  • Established cell line for the use in determining HIV-1 phenotype, with the
  • Properties: human, immortalized, CD4 positive T lymphocyte, derived from a homozygous CCR5 negative donor, expressing a functional CXCR4 coreceptor for HIV-1
  • Simple cell culture system for determining coreceptor usage.
  • Permanent availability of appropriate cells for HIV phenotyping.
  • Early detection of coreceptor switch.
  • Capability for standarized evaluation of HIV phenotype

Broad-Range Disinfection of Bacteria, Viruses, Fungi and Prions


07.11.2008 | Ref.Nr. 07073
Download as PDF PDF Download Share
Life Science › Pharma&Biotech

An ideal disinfectant should have no protein fixating effects, a fast and highly efficient decontaminating/ inactivating activity on a broad range of bacteria, viruses, fungi as well as on prions and should be non-corrosive to instruments and easy to use.

Scientists from the Robert Koch-Institute developed a disinfectant which meets all these requirements. The developed disinfectant is a new formulation for chemical disinfection consisting of three components: a detergent, an alkali hydroxide and an alcohol. Furthermore, it has no fixating effects and is active on a broad range of bacteria, viruses, fungi as well as prions. Inactivation of all these pathogens resulting in a reduction factor of log 4 or more takes place at room temperature within an incubation time of only 10-20 minutes. The new disinfectant allows for fast and highly efficient decontamination at user and instrument friendly conditions. The formulation has been tested under various conditions including those in which the contaminants are enclosed in brain homogenate or blood. 

Typical applications for the newly developed disinfectant are the decontamination of surgical, dental, diagnostic and laboratory instruments as well as other medical devices.


IP Rights
EP 07023996.7 filed on December 11, 2007

Origin
The invention was made at the Robert-Koch Instituts

 

Application Area:
Hygiene in Medical, Care
Development Stage: Lab scale
Type of Collaboration: License an Cooperation
Schlagworte: Bacteria, Disinfectant, Fungi, Instrument Friendly, Non-Corrosive, Prion, Viruses,
Weitere Kategorien: Diagnostics, Life Science, Immunology & Infection, Immunology & Infection, Pharma & Biotech
Bild des Benutzers Jeanne Trommer
Licensing Manager: Jeanne Trommer
T +49 30 2125 4831
F +49 30 2125 4822
jeanne.trommer@ipal.de
Market Potential: Worldwide
Benefits:

  • Fast and efficient broad range disinfection including non-enveloped viruses, mycobacteria and prions
  •  Non-protein fixating
  •  Active on agents enclosed in blood
  •  Easy to use